CJC-1295 No DAC Dosaging Guide
Research Disclaimer Content on this page is for research and educational purposes only. BioLabDirect products are sold as research chemicals and are not for human or veterinary use, diagnosis, treatment, or disease prevention. Nothing here is medical advice, a dosing protocol, or a clinical claim. Always follow institutional lab policies and applicable regulations.
For Research Purposes Only.
This CJC-1295 No DAC dosaging guide is for laboratory researchers who need clear arithmetic and quality-check practice for this GHRH-analog research peptide: how the name is used, how to calculate stock concentration from a 10 mg vial, how to store aliquots, and how to read the mass on a Certificate of Analysis. It gives no instructions for use in people or animals and makes no medical claims. See the full research peptide catalog for other materials.
Internal resources:
- CJC-1295 No DAC research peptide (10mg vial)
- Peptide reconstitution calculator
- COA library (third-party lab reports)
- TB-500 Dosaging Guide · BPC-157 Dosaging Guide
- Related research peptides: TB-500 · BPC-157
What “CJC-1295 No DAC” Means in a Research Context
CJC-1295 No DAC is generally described by suppliers as a modified hGRF(1–29) analog without the maleimido linker (the Drug Affinity Complex, “DAC”) that Jetté et al. (2005) used for albumin conjugation. No paper cited on this page studies the No-DAC form directly, so confirm the sequence and observed mass on the lot CoA rather than relying on the name.
Jetté et al. (2005) describe CJC-1295 as a tetrasubstituted form of hGRF(1–29) with an added maleimidopropionamide lysine at the C terminus, designed to bind serum albumin. Their stability and pharmacokinetic results concern that albumin-conjugating version and should not be assumed to apply to the No-DAC form. Memdouh et al. (2021) is an anti-doping analytical study of in vitro metabolism and LC-MS/MS urine detection of GHRH analogs, including CJC-1295 with and without DAC; it is cited here only as a source of mass-spectrometry reference information.
| Item | Detail for lab planning |
|---|---|
| Name | CJC-1295 No DAC (supplier name; modified hGRF(1–29) analog) |
| Form supplied | Lyophilized powder, 10 mg vial |
| Sequence and mass | Take from the lot CoA |
GHRH Receptor Background
GHRH analogs are studied through the GHRH receptor (GHRH-R). Petersenn and Schulte (2000) review its structure and function, reporting that the human GHRH-R gene encodes a 423-amino-acid protein of about 47 kDa, and discussing signal transduction and transcriptional regulation. Jetté et al. (2005) used a secretion assay in cultured rat anterior pituitary cells and reported improved in vitro stability against dipeptidylpeptidase-IV for their albumin conjugates, which are not the No-DAC form.
These are findings in defined systems; read the primary papers for methods and limits.
Reconstitution and Concentration Math for Laboratory Research
The arithmetic is two lines: stock concentration equals peptide mass divided by diluent volume, and the volume for an assay equals the target mass divided by the stock concentration. Work in one unit system (1 mg = 1,000 µg) and substitute net peptide content from the CoA where it is reported. The peptide reconstitution calculator performs the same calculation.
| Step | Calculation | Result |
|---|---|---|
| 1. Vial content | Label amount | 10 mg of CJC-1295 No DAC |
| 2. Diluent added | Chosen by the lab for the assay | 2 mL |
| 3. Stock concentration | 10 mg ÷ 2 mL | 5 mg/mL (5,000 µg/mL) |
| 4. Example working aliquot | 250 µg ÷ 5,000 µg/mL | 0.05 mL (50 µL) |
This is a unit-conversion illustration with an arbitrary 250 µg target, not an amount taken from a study or a recommendation. Record the diluent volume you actually use.
What the Published Literature Does and Doesn’t Specify
The quantitative data in the CJC-1295 literature are tied to specific preparations (for example, the albumin-conjugating form in rats) and specific assays, so they do not transfer to the No-DAC form. This guide therefore lists no numerical amounts. For experimental design, use the methods of the primary paper closest to your model, apply your institution’s approvals, and let the calculator convert targets into volumes.
Storage and Handling for a 10 mg CJC-1295 No DAC Vial
- Store unopened vials as the lot CoA specifies (sealed, cold, dry, protected from light).
- After reconstitution, divide the stock into single-use aliquots; at 5 mg/mL, 100 µL holds 500 µg, so a 2 mL stock gives 20 such aliquots.
- As with most peptides, material in solution can degrade over time, so keep solution time short and temperature low, and validate stability in your own buffer (general principles: Manning et al., 2010).
- Record date, diluent and concentration on every tube.
Reading the CoA: No DAC vs DAC Mass
Because the DAC and No-DAC analogs share a core sequence, mass spectrometry is the decisive identity check. Confirm that:
- the lot number on the vial matches the report;
- the observed mass corresponds to the unconjugated No-DAC peptide and not a linker-bearing variant;
- HPLC purity, test date and testing laboratory are stated and traceable.
Reports are in the COA library.
Frequently Asked Questions
What does "No DAC" mean?
DAC stands for Drug Affinity Complex, the maleimido-lysine linker that allows binding to serum albumin. “No DAC” indicates the analog is supplied without that linker; confirm on the lot CoA.
Does the cited research apply to the No-DAC form?
Not directly. Jetté et al. (2005) studied the albumin-conjugating CJC-1295, and Memdouh et al. (2021) is an analytical detection study. Neither establishes properties of the No-DAC form.
How do I calculate stock concentration for a 10 mg vial?
Divide mass by diluent volume: 10 mg in 2 mL is 5 mg/mL (5,000 µg/mL). The calculator covers other volumes. This is laboratory arithmetic only.
Why does this guide give no amounts?
The published data are specific to particular preparations and models. Nothing here is guidance for use in people or animals.
How do I confirm I have the No-DAC form?
Compare the observed mass on the lot report in the COA library with the unconjugated peptide mass, and check that the lot number matches your vial.
References
Please read each full paper before relying on any detail.
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID: 15817669. DOI: 10.1210/en.2004-1286.
- Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871–1887. (anti-doping analytical study) PMID: 34665524. DOI: 10.1002/dta.3183.
- Petersenn S, Schulte HM. Structure and function of the growth-hormone-releasing hormone receptor. Vitam Horm. 2000;59:35–69. PMID: 10714236. DOI: 10.1016/s0083-6729(00)59003-7.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. PMID: 20143256. DOI: 10.1007/s11095-009-0045-6.
Research Disclaimer This article is educational only. BioLabDirect sells research chemicals not intended for human consumption or clinical use. No statement here establishes safety or effectiveness for any condition, and nothing here is a recommendation for any person or animal. Follow institutional biosafety rules.
For Research Purposes Only.
